Trademark: 79342263
Word
ILLIMIS
Status Date
Tuesday, July 4, 2023
Registration Number
7095522
Registration Date
Tuesday, July 4, 2023
Filing Date
Thursday, March 17, 2022
Published for Opposition
Tuesday, April 18, 2023
5 Pharmaceutical preparations for the treatment of auto-immune diseases; pharmaceutical agents affecting sensory organs; pharmaceutical agents affecting peripheral nervous system; pharmaceutical preparations for activating cellular function; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for respiratory organs; pharmaceutical preparations for the prevention of disorders of the nervous system; pharmaceutical preparations for the treatment of cardiovascular disease; pharmaceutical preparations for the treatment of inflammatory diseases; ophthalmic preparations; pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations for the treatment of degenerative brain disease; pharmaceutical preparations for the treatment of brain dysfunction; pharmaceutical preparations for the treatment of stroke; pharmaceutical preparations for the treatment of cerebrovascular disease; pharmaceutical preparations for the treatment of dementia; pharmaceutical preparations for the treatment of Alzheimer's disease; pharmaceutical preparations for use in the treatment of solid tumors and growths, hemolytic diseases and disorders, amyloidosis, metabolic diseases and disorders, lupus, and inflammation and autoimmune diseases and disorders
42 Pharmaceutical product development; pharmaceutical research and development of medicines in the field of age-related diseases/disorders and degenerative diseases; pharmaceutical research and development of medicines in the field of chronic malady/disease and dysfunction; scientific research for medical purposes in the field of gene therapy; medical scientific research in the field of brain disease; medical scientific research in the field of neurological diseases; biotechnology research and scientific and pharmaceutical research in the antibody field; biological research; scientific research in the field of cancer disease; remote monitoring and quality control inspection for others of active substances in the pharmaceutical research field and scientific analysis of active substances in the pharmaceutical research field; research for quality inspection related to human hygiene management for medical research purposes; scientific and medical research of autoimmune disease; development of pharmaceutical preparations for cell therapy; stem cell collection for medical research; cell processing and culture for medical research; pharmaceutical research and development of medicines in the field of inflammatory disease; pharmaceutical research and development of medicines in the field of eye disease; pharmaceutical research and development of medicines in the field of amyloidosis; consultancy pertaining to pharmacology relating to pharmaceutical quality control; providing information on the research of medical products relating to pharmaceutical quality control
Oct 31, 2023
Final Decision Transaction Processed By Ib
Oct 6, 2023
Final Disposition Notice Sent To Ib
Oct 6, 2023
Final Disposition Processed
Oct 4, 2023
Final Disposition Notice Created, To Be Sent To Ib
Jul 4, 2023
Notice Of Registration Confirmation Emailed
Jul 4, 2023
Registered-Principal Register
May 10, 2023
Limitation From The Ib Examined And Entered
Apr 25, 2023
Notification Processed By Ib
Apr 18, 2023
Official Gazette Publication Confirmation E-Mailed
Apr 18, 2023
Published For Opposition
Apr 5, 2023
Notification Of Possible Opposition Sent To Ib
Apr 5, 2023
Notice Of Start Of Opposition Period Created, To Be Sent To Ib
Mar 29, 2023
Notification Of Notice Of Publication E-Mailed
Mar 21, 2023
Refusal Processed By Ib
Mar 11, 2023
Approved For Pub - Principal Register
Mar 7, 2023
Teas/Email Correspondence Entered
Mar 7, 2023
Correspondence Received In Law Office
Mar 7, 2023
Teas Response To Office Action Received
Feb 27, 2023
Non-Final Action Mailed - Refusal Sent To Ib
Feb 27, 2023
Refusal Processed By Mpu
Feb 13, 2023
Limitation Of Goods Received From Ib
Jan 1, 2023
Non-Final Action (Ib Refusal) Prepared For Review
Dec 31, 2022
Non-Final Action Written
Dec 29, 2022
Assigned To Examiner
Jun 14, 2022
Application Filing Receipt Mailed
Jun 10, 2022
New Application Office Supplied Data Entered
Jun 9, 2022
Sn Assigned For Sect 66a Appl From Ib
Trademark Alertz updated from USPTO on 2030-01-24
